Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2017 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Down 10.89%

The earnings report shows that Madrigal Pharmaceuticals is still in a development phase, with no revenue reported. The stock fell significantly by 10.89%, likely due to investor disappointment over the lack of guidance and clarity on future performance. This decline reflects concerns about the company's ability to generate revenue in the near term.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.67	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management emphasized their commitment to advancing their clinical programs. However, they did not provide any updates on future guidance.

Management did not provide specific guidance for future quarters.

The company is focusing on ongoing clinical trials and research.

Madrigal Pharmaceuticals Misses on EPS, Stock Down 10.89%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Down 10.89%

Key numbers

Management commentary